These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
449 related articles for article (PubMed ID: 29326440)
1. BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines. Herr R; Halbach S; Heizmann M; Busch H; Boerries M; Brummer T Oncogene; 2018 Mar; 37(12):1576-1593. PubMed ID: 29326440 [TBL] [Abstract][Full Text] [Related]
2. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320 [TBL] [Abstract][Full Text] [Related]
3. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323 [TBL] [Abstract][Full Text] [Related]
4. BRAF and EGFR inhibitors synergize to increase cytotoxic effects and decrease stem cell capacities in BRAF(V600E)-mutant colorectal cancer cells. Wu Z; Huang M; Gong Y; Lin C; Guo W Acta Biochim Biophys Sin (Shanghai); 2018 Apr; 50(4):355-361. PubMed ID: 29534162 [TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495 [TBL] [Abstract][Full Text] [Related]
6. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Prahallad A; Sun C; Huang S; Di Nicolantonio F; Salazar R; Zecchin D; Beijersbergen RL; Bardelli A; Bernards R Nature; 2012 Jan; 483(7387):100-3. PubMed ID: 22281684 [TBL] [Abstract][Full Text] [Related]
7. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Sun C; Wang L; Huang S; Heynen GJ; Prahallad A; Robert C; Haanen J; Blank C; Wesseling J; Willems SM; Zecchin D; Hobor S; Bajpe PK; Lieftink C; Mateus C; Vagner S; Grernrum W; Hofland I; Schlicker A; Wessels LF; Beijersbergen RL; Bardelli A; Di Nicolantonio F; Eggermont AM; Bernards R Nature; 2014 Apr; 508(7494):118-22. PubMed ID: 24670642 [TBL] [Abstract][Full Text] [Related]
8. Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells. Song Q; Sun X; Guo H; Yu Q Oncotarget; 2017 Jan; 8(3):5003-5015. PubMed ID: 28002807 [TBL] [Abstract][Full Text] [Related]
9. Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers. Kotani H; Adachi Y; Kitai H; Tomida S; Bando H; Faber AC; Yoshino T; Voon DC; Yano S; Ebi H Oncogene; 2018 Mar; 37(13):1775-1787. PubMed ID: 29348459 [TBL] [Abstract][Full Text] [Related]
10. Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer. Yang L; Bhattacharya A; Li Y; Sexton S; Ling X; Li F; Zhang Y J Exp Clin Cancer Res; 2022 Jun; 41(1):184. PubMed ID: 35650607 [TBL] [Abstract][Full Text] [Related]
11. Tumor suppressor miR-193a-3p enhances efficacy of BRAF/MEK inhibitors in BRAF-mutated colorectal cancer. Hiraide S; Takahashi M; Yoshida Y; Yamada H; Komine K; Ishioka C Cancer Sci; 2021 Sep; 112(9):3856-3870. PubMed ID: 34288281 [TBL] [Abstract][Full Text] [Related]
12. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Corcoran RB; Ebi H; Turke AB; Coffee EM; Nishino M; Cogdill AP; Brown RD; Della Pelle P; Dias-Santagata D; Hung KE; Flaherty KT; Piris A; Wargo JA; Settleman J; Mino-Kenudson M; Engelman JA Cancer Discov; 2012 Mar; 2(3):227-35. PubMed ID: 22448344 [TBL] [Abstract][Full Text] [Related]
13. MUC1-C is necessary for SHP2 activation and BRAF inhibitor resistance in BRAF(V600E) mutant colorectal cancer. Morimoto Y; Yamashita N; Hirose H; Fushimi A; Haratake N; Daimon T; Bhattacharya A; Ahmad R; Suzuki Y; Takahashi H; Kufe DW Cancer Lett; 2023 Apr; 559():216116. PubMed ID: 36878307 [TBL] [Abstract][Full Text] [Related]
14. Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer. Kawakami H; Huang S; Pal K; Dutta SK; Mukhopadhyay D; Sinicrope FA Mol Cancer Ther; 2016 Dec; 15(12):3015-3027. PubMed ID: 27765849 [TBL] [Abstract][Full Text] [Related]
16. Antibody dependent cellular cytotoxicity-inducing anti-EGFR antibodies as effective therapeutic option for cutaneous melanoma resistant to BRAF inhibitors. Muraro E; Montico B; Lum B; Colizzi F; Giurato G; Salvati A; Guerrieri R; Rizzo A; Comaro E; Canzonieri V; Anichini A; Del Vecchio M; Mortarini R; Milione M; Weisz A; Pizzichetta MA; Simpson F; Dolcetti R; Fratta E; Sigalotti L Front Immunol; 2024; 15():1336566. PubMed ID: 38510242 [TBL] [Abstract][Full Text] [Related]
17. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644 [TBL] [Abstract][Full Text] [Related]
18. Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer. Hu S; Dai H; Li T; Tang Y; Fu W; Yuan Q; Wang F; Lv G; Lv Y; Fan X; Zhang S; Jin R; Shen Y; Lin F; Ye X; Ding M; Yang Y; Lei C Cancer Lett; 2016 Nov; 382(1):32-43. PubMed ID: 27569653 [TBL] [Abstract][Full Text] [Related]
19. IL6/STAT3 axis mediates resistance to BRAF inhibitors in thyroid carcinoma cells. Notarangelo T; Sisinni L; Trino S; Calice G; Simeon V; Landriscina M Cancer Lett; 2018 Oct; 433():147-155. PubMed ID: 29969659 [TBL] [Abstract][Full Text] [Related]
20. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines. Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]